{
  "report_rows": [
    {
      "kpi": "Q2 2026 Adjusted Diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$4.05 vs. cons ~$3.95",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Total Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$3.56B vs. cons ~$3.51B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "U.S. Dialysis Treatments-per-Normalized-Day Growth y/y",
      "prediction": "BEAT",
      "answer": "pred ~+65bps vs. cons ~+40bps",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted Diluted EPS Guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$14.50-$15.60 (midpoint ~$15.05) vs. cons ~$15.07 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Adjusted Operating Income Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$2.20B-$2.32B (midpoint ~$2.26B) vs. cons ~$2.23B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 U.S. Dialysis Volume Growth Guidance",
      "prediction": "BETTER",
      "answer": "guide ~+50 to +75bps vs. cons/prior guide ~+25 to +50bps (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "ACA/OBBBA Marketplace Revenue Headwind Commentary",
      "prediction": "UNCHANGED",
      "answer": "guide ~$35-40M headwind vs. prior guide ~$40M (FY2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.3,
  "day5_path": "FADE",
  "day5_rationale": "A likely EPS/revenue beat and modest guidance raise are already substantially priced in after the stock's 100%+ YTD run and a rally to levels above average sell-side targets (note the pre-print pullback from ~$240 to ~$234). The full-year raise implied by a Q2 beat is arithmetically modest (H2 comps get tougher, RPT tailwinds normalize, ACA/OBBBA mix drag persists), so out-period estimate revisions likely lag the magnitude of the quarter's beat, prompting profit-taking and a fade of any initial pop over the following days, consistent with Berkshire/insider selling overhang and stretched leverage/valuation.",
  "day5_confidence": "MEDIUM"
}